Esperion Therapeutics Earns Buy Rating from HC Wainwright
ESPR Stock | USD 2.80 0.26 10.24% |
Slightly above 71 percent of all Esperion Therapeutics' retail investors are curious in acquiring. The analysis of the overall investor sentiment regarding Esperion Therapeutics suggests that quite a few traders are confidant. Esperion Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Esperion Therapeutics. Many technical investors use Esperion Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Esperion |
HC Wainwright restated their buy rating on shares of Esperion Therapeutics in a research report sent to investors on Friday morning,Benzinga reports. The brokerage currently has a 16.00 target price on the biopharmaceutical companys stock. HC Wainwright also issued estimates for Esperion Therapeutics FY2025 earnings at 1.36 EPS, FY2026 earnings at
Read at thelincolnianonline.com
Esperion Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Esperion Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Esperion Therapeutics Fundamental Analysis
We analyze Esperion Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Esperion Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Esperion Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Asset
Total Asset Comparative Analysis
Esperion Therapeutics is currently under evaluation in total asset category among its peers. Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Esperion Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Esperion Therapeutics stock to make a market-neutral strategy. Peer analysis of Esperion Therapeutics could also be used in its relative valuation, which is a method of valuing Esperion Therapeutics by comparing valuation metrics with similar companies.
Peers
Esperion Therapeutics Related Equities
RMTI | Rockwell Medical | 3.15 | ||||
PCRX | Pacira BioSciences, | 1.62 | ||||
KMDA | Kamada | 1.38 | ||||
PBH | Prestige Brand | 0.71 | ||||
ELAN | Elanco Animal | 0.61 | ||||
CTLT | Catalent | 0.18 | ||||
NBIX | Neurocrine Biosciences | 0.13 | ||||
COLL | Collegium Pharmaceutical | 0.68 | ||||
PAHC | Phibro Animal | 0.93 | ||||
AVDL | Avadel Pharmaceuticals | 0.98 | ||||
ALKS | Alkermes Plc | 1.02 | ||||
SIGA | SIGA Technologies | 1.09 | ||||
ITCI | Intracellular | 1.09 | ||||
LFCR | Lifecore Biomedical | 1.20 | ||||
ANIP | ANI Pharmaceuticals | 3.64 | ||||
IRWD | Ironwood Pharmaceuticals | 4.09 |
Additional Tools for Esperion Stock Analysis
When running Esperion Therapeutics' price analysis, check to measure Esperion Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Esperion Therapeutics is operating at the current time. Most of Esperion Therapeutics' value examination focuses on studying past and present price action to predict the probability of Esperion Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Esperion Therapeutics' price. Additionally, you may evaluate how the addition of Esperion Therapeutics to your portfolios can decrease your overall portfolio volatility.